The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab

Novel therapeutics for hemophilia and other bleeding disorders

(2018) Michael U. Callaghan et al.   BLOOD

Emerging therapies for haemophilia - Global perspective

(2018) J. Mahlangu et al.   HAEMOPHILIA

Immune tolerance induction: What have we learned over time?

(2018) H.-H. Brackmann et al.   HAEMOPHILIA

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

(2018) Johnny Mahlangu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluating the safety of emicizumab in patients with hemophilia A

(2018) Arielle L Langer et al.   Expert Opinion On Drug Safety

First-line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties

(2017) P. Collins et al.   HAEMOPHILIA

Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis

(2017) F. Peyvandi et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

(2017) Johannes Oldenburg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Strategies to target long-lived plasma cells for treating hemophilia A inhibitors

(2016) Chao Lien Liu et al.   CELLULAR IMMUNOLOGY

Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/VWF product: the long-term ITI study

(2016) V. Jiménez-Yuste et al.   HAEMOPHILIA

A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A

(2016) Flora Peyvandi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of inhibitors on hemophilia a mortality in the United States

(2015) Christopher E. Walsh et al.   AMERICAN JOURNAL OF HEMATOLOGY

Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two US centres

(2015) C. Nakar et al.   HAEMOPHILIA

First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study

(2015) W. Kreuz et al.   HAEMOPHILIA

Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment

(2015) S. R. Earnshaw et al.   HAEMOPHILIA

Inhibitor development and mortality in non-severe hemophilia A

(2015) C. L. Eckhardt et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Complications of Central Venous Access Devices: A Systematic Review

(2015) A. J. Ullman et al.   PEDIATRICS

Toward optimal therapy for inhibitors in hemophilia

(2014) C. L. Kempton et al.   BLOOD

Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product

(2014) S. Rangarajan et al.   HAEMOPHILIA

Inhibitors in patients with haemophilia A

(2014) Wolfhart Kreuz et al.   THROMBOSIS RESEARCH

Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate

(2013) J. Oldenburg et al.   HAEMOPHILIA

How we choose factor VIII to treat hemophilia

(2012) P. M. Mannucci et al.   BLOOD

The principal results of the International Immune Tolerance Study: a randomized dose comparison

(2011) C. R. M. Hay et al.   BLOOD

Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia

(2010) P. W. COLLINS et al.   HAEMOPHILIA

The long-term course of factor VIII inhibitors in patients with congenital haemophilia A without immune tolerance induction

(2010) C. Caram et al.   THROMBOSIS AND HAEMOSTASIS